Shanghai Pharmaceuticals Holding Co., Ltd (HKG:2607)

HKG:2607 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	276,310	274,187	259,152	231,240	215,824	191,423
Other Revenue	1,120	1,064	1,143	741.24	-	485.96
Revenue	277,431	275,251	260,295	231,981	215,824	191,909
Revenue Growth (YoY)	3.86%	5.75%	12.21%	7.49%	12.46%	2.86%
Cost of Revenue	248,129	244,837	229,366	201,604	187,416	165,671
Gross Profit	29,301	30,413	30,929	30,377	28,408	26,238
Selling, General & Admin	17,731	18,326	19,527	19,173	18,376	16,797
Research & Development	2,248	2,394	2,204	2,112	1,987	1,657
Other Operating Expenses	689.81	712.38	376.86	654.72	633.18	587.25
Operating Expenses	21,035	21,665	22,349	22,214	20,942	18,956
Operating Income	8,267	8,748	8,581	8,164	7,466	7,282
Interest Expense	-1,827	-1,857	-1,885	-1,689	-1,518	-1,412
Interest & Investment Income	3,833	902.81	461.83	971.41	2,150	1,265
Currency Exchange Gain (Loss)	-94.78	-73.93	11.41	21.51	10.1	-41.43
Other Non Operating Income (Expenses)	-29.81	-72.07	-109.59	-116.44	-128.71	-119.03
EBT Excluding Unusual Items	10,149	7,648	7,059	7,351	7,979	6,974
Impairment of Goodwill	-395.02	-230.47	-	-	-19.21	-486.27
Gain (Loss) on Sale of Investments	139.89	178.43	155.93	218.74	-206	116.8
Gain (Loss) on Sale of Assets	88.64	187.97	92.48	1,439	58.29	52.15
Asset Writedown	-539.81	-218.05	-70.65	-322.79	-69.77	-15.77
Legal Settlements	-23.96	-26.56	-12.69	-37.38	-8.1	-34.82
Other Unusual Items	600.23	480.29	-169.95	160.13	409.61	569.14
Pretax Income	10,019	8,020	7,054	8,808	8,144	7,175
Income Tax Expense	2,751	2,150	1,888	1,816	1,869	1,570
Earnings From Continuing Operations	7,267	5,870	5,167	6,992	6,275	5,605
Minority Interest in Earnings	-1,198	-1,317	-1,399	-1,375	-1,181	-1,109
Net Income	6,069	4,553	3,768	5,617	5,093	4,496
Net Income to Common	6,069	4,553	3,768	5,617	5,093	4,496
Net Income Growth	48.03%	20.82%	-32.92%	10.28%	13.28%	10.17%
Shares Outstanding (Basic)	3,707	3,704	3,701	3,483	2,842	2,842
Shares Outstanding (Diluted)	3,707	3,704	3,701	3,483	2,842	2,842
Shares Change (YoY)	0.09%	0.07%	6.28%	22.54%	-	-
EPS (Basic)	1.64	1.23	1.02	1.61	1.79	1.58
EPS (Diluted)	1.64	1.23	1.02	1.61	1.79	1.58
EPS Growth	48.84%	20.73%	-36.77%	-10.06%	13.29%	10.04%
Free Cash Flow	4,169	3,426	2,261	2,058	942.55	3,835
Free Cash Flow Per Share	1.13	0.93	0.61	0.59	0.33	1.35
Dividend Per Share	0.290	0.370	0.410	0.610	0.420	0.480
Dividend Growth	-40.82%	-9.76%	-32.79%	45.24%	-12.50%	9.09%
Gross Margin	10.56%	11.05%	11.88%	13.10%	13.16%	13.67%
Operating Margin	2.98%	3.18%	3.30%	3.52%	3.46%	3.79%
Profit Margin	2.19%	1.65%	1.45%	2.42%	2.36%	2.34%
Free Cash Flow Margin	1.50%	1.24%	0.87%	0.89%	0.44%	2.00%
EBITDA	9,932	10,270	10,081	9,689	8,973	8,779
EBITDA Margin	3.58%	3.73%	3.87%	4.18%	4.16%	4.57%
D&A For EBITDA	1,666	1,522	1,500	1,526	1,507	1,496
EBIT	8,267	8,748	8,581	8,164	7,466	7,282
EBIT Margin	2.98%	3.18%	3.30%	3.52%	3.46%	3.79%
Effective Tax Rate	27.46%	26.81%	26.76%	20.62%	22.95%	21.88%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.